The well-known TRED-HF trial resulted in a 40% relapse of HF rate six months after withdrawing all HF medication including angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker, beta blocker, mineralocorticoid receptor antagonist, and loop diuretics [3]. This evidence concerns the gene NR3C2 and hydrops fetalis.